Author of

• 28971

  +

  Lunch & Poster Display session (ID 58)

  • Event: ELCC 2019
  • Type: Poster Display session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1

  • 29024

    +

    61P - Value of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model (ID 292)

    12:30 - 13:00  |  Author(s): Wen Ouyang
    • Abstract
    • Slides

    Background
    

    Small cell lung carcinoma (SCLC) rarely underwent surgical treatment. The aim of the study was to investigate the value of postoperative radiotherapy for limited stage small cell lung cancer based on a prognostic scoring model.

    a9ded1e5ce5d75814730bb4caaf49419 Methods
    

    We searched the Surveillance, Epidemiology, and End Results (SEER) database for all cases of limited stage SCLC treated by surgical resection and chemotherapy between 2004-2014. A prognostic scoring model was built to evaluate the prognostic value of postoperative radiotherapy on the basis of a Cox proportional hazards model. Overall survival (OS) and cancer-specific survival (CSS) was compared in the different risk groups.

    20c51b5f4e9aeb5334c90ff072e6f928 Results
    

    Table: 61P

    Multivariable analysis of the association between clinical variables and overall survival (N = 767)

    OS
    Variables	HR (95%CI)	P
    Age (>65 vs ≤ 65 y)	1.35 (1.17-1.57)	<0.001
    Race (White vs non-white)	1.18 (0.90-1.55)	0.238
    Sex (Male vs Female)	1.33 (1.15-1.54)	<0.001
    Grade (Poor/ undifferentiated vs Well/Moderately/NOS	0.99 (0.86-1.15)	0.922
    Lymph Node Stage (N+ vs N-)	1.36 (1.17-1.58)	0.001
    T stage (T3/4 vs T1/2)	1.31 (1.08-1.58)	0.005
    Laterality (Left vs Right vs NOS)	1.04 (0.91-1.19)	0.55
    Primary lobe (Main bronchus vs Upper vs Middle vs Lower vs Overlapping lesion of lung or NOS)	1.01 (0.94-1.09)	0.717

    fd69c5cf902969e6fb71d043085ddee6 Conclusions
    

    On the basis of the prognostic scoring model, postoperative-radiotherapy in addition to surgery provides better outcomes than surgery alone for limited stage SCLC in high risk group. Prospective studies are needed to validate these results.

    b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study
    

    Jing Yu.

    213f68309caaa4ccc14d5f99789640ad Funding
    

    Has not received any funding.

    682889d0a1d3b50267a69346a750433d Disclosure
    

    All authors have declared no conflicts of interest.

    cffcb1a185b2d7d5c44e9dc785b6bb25

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.